HRA-19a1.1

Human colorectal adenocarcinoma

STR-PCR Data:

Amelogenin: X,Y
CSF1PO: 12
D13S317: 12,12
D16S539: 11
D5S818: 11
D7S820: 9,12
THO1: 8
TPOX: 11
vWA: 16

The HRA-19 cell line was established from a primary human rectal adenocarcinoma present in a 66-year old male. The adenocarcinoma was well differentiated and determined to be Dukes′ stage B. The HRA-19a1.1 cell line is a clone of HRA-19. HRA-19 has stem cell properties and undergoes a multilineage differentiation in serum free medium.

DMEM - high glucose (D6546) + 2 mM L-Glutamine (G7513) + 10% FBS / FCS (F2442).

Split sub-confluent cultures (70-80%) 1:5 to 1:6 weekly using 0.05% trypsin/EDTA; 7.5% CO₂; 37 °C. Suggested seeding density 2-4x10,000 cells/cm².

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). Use of this product by commercial organizations may require a license agreement. Commercial customers will be contacted by cellscreening@merckgroup.com to provide further information after the order request is submitted. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.